Correlation of gene expression with disease activity in patients with RA and PsA.
| Form of arthritis | Spearman’s ρ (95% CI) | p* |
|---|---|---|
| RA | ||
| Runx2 vs | ||
| Larsen score | –0.32 (–0.57 to 0.01) | 0.04 |
| Physician assessment of disease activity | –0.29 (–0.53 to 0.01) | 0.04 |
| DAS28 | –0.40 (–0.61 to 0.13) | <0.01 |
| BMP-4 vs | ||
| Physician assessment of disease activity | –0.28 (–0.52 to 0.01) | 0.05 |
| Patient assessment of fatigue | –0.28 (–0.52 to 0.01) | 0.05 |
| DAS28 | –0.28 (–0.52 to 0.01) | 0.05 |
| FasL vs | ||
| Physician assessment of disease activity | –0.33 (–0.56 to 0.05) | 0.02 |
| Patient assessment of fatigue | –0.29 (–0.53 to 0.00) | 0.05 |
| PsA | ||
| Runx2 vs | ||
| Enthesial pain | –0.54 (–0.8 to 0.12) | 0.02 |
| BMP-4 vs | ||
| Patient assessment of disease activity | 0.54 (0.12 to 0.79) | 0.02 |
| Patient assessment of pain | 0.49 (0.06 to 0.77) | 0.04 |
| BASDAI | 0.46 (0.02 to 0.75) | 0.04 |
↵* Gene expression values were correlated with clinical data using rank correlation and Spearman’s coefficient ρ with its 95% confidence interval (CI). Significant correlation was found in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).